Dexrazoxane prevents vascular toxicity in doxorubicin-treated mice
Our results not only confirm the cardioprotective effects of DEXRA against DOX-induced cardiotoxicity but also add preservation of vascular endothelial cell function as an important mechanism. Moreover, the study demonstrates the potential of SERPINA3N as a biomarker for monitoring cardiovascular complications of DOX in high-risk patients.
Authors
- Matthias Bosman (ORCID: https://orcid.org/0000-0001-9102-5366)
- Emeline M. Van Craenenbroeck (ORCID: https://orcid.org/0000-0001-7686-2668)
- Dustin N. Krüger (ORCID: https://orcid.org/0000-0003-0752-3819)
- Guido R.Y. De Meyer (ORCID: https://orcid.org/0000-0003-3848-8702)
- Pieter‐Jan Guns (ORCID: https://orcid.org/0000-0002-8640-6620)
- Constantijn Franssen (ORCID: https://orcid.org/0000-0002-7085-5317)
Institutions
- University of Antwerp (BE)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1186/s40959-024-00270-w
- Citations
- 8
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- European Commission
- Fonds Wetenschappelijk Onderzoek
- Koning Boudewijnstichting
- Universiteit Antwerpen
- Vlaamse regering
- Fondation contre le Cancer
- Horizon 2020 Framework Programme